bluebird bio
At bluebird bio, our goal is to recode the science, the system – and even the status quo – for life.
We’re working toward four potential product approvals by 2022 and a pipeline ready to tackle a range of severe diseases. Powered by multiple labs, in-house lentiviral vector manufacturing capabilities and future drug product production, we push ourselves to find answers for the people who need them by exploring the cutting-edge spectrum of gene therapy.